- Home
- BIIB
BIIB
Biogen Inc.
as 04-03-2025 4:00pm EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 19.9B | IPO Year: | 1991 |
| Target Price: | $220.50 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.18 | EPS Growth: | 40.28 |
| 52 Week Low/High: | $128.51 - $238.00 | Next Earning Date: | 04-23-2025 |
| Revenue: | $9,675,900,000 | Revenue Growth: | -1.62% |
| Revenue Growth (this year): | -2.84% | Revenue Growth (next year): | -0.35% |
Stock Insider Trading Activity of Biogen Inc. (BIIB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SHERWIN STEPHEN A | BIIB | Director | Mar 7 '25 | Sell | $150.02 | 8,760 | $1,314,141.91 | 11,318 |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
MT Newswires
16 hours ago
RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating
Pharmaceutical Technology
2 days ago
Organon acquires Actemra biosimilar’s US rights from Biogen
MT Newswires
2 days ago
Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation
GlobeNewswire
2 days ago
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
MT Newswires
3 days ago
Organon Acquires Tofidence for Intravenous Infusion in US
Simply Wall St.
3 days ago
Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years
Investor's Business Daily
4 days ago
Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?
BioPharma Dive
7 days ago
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.